stockrow
Friday 6 November 2026
Export RGC’s income statement to Excel — free account
Regencell Bioscience Holdings Limited
RGC Healthcare Drug Manufacturers Specialty & Generic
5.32
0.05
+0.95%
Follow RGC
Alert me
Regencell Bioscience Holdings Limited (RGC) P/E ratio
Regencell Bioscience Holdings Limited has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| XERS Xeris Biopharma Holdings, Inc. compare | n/m |
| PRGO Perrigo Company plc compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| RGC Regencell Bioscience Holdings Limited | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| AMLX Amylyx Pharmaceuticals, Inc. compare | n/m |
| TRLV Trulieve Cannabis Corp. compare | n/m |
| PBH Prestige Consumer Healthcare Inc. compare | 13.7× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)